For Young Women with Breast Cancer, Aggressive Surgery May Not Mean Better Outcomes

When facing a breast cancer diagnosis at a young age, many women assume that a mastectomy offers the best chance of survival. According to new research from Columbia University Irving Medical Center, that is not always the case. Researchers found that women under 40 who underwent breast-conserving therapy had outcomes comparable to those who chose mastectomy, as well as to post-menopausal women with the same diagnosis. 

Breast-conserving therapy combines a lumpectomy, a surgery to remove the cancerous tissue and a small margin of surrounding tissue, plus radiation therapy to eliminate any remaining cancer cells in the breast. Mastectomy, by contrast, removes the entire breast, often with reconstruction.

Balancing aggressive treatment with outcomes

“For a long time, we have known that for average-risk breast cancer patients, a more aggressive surgical treatment is not associated with a better outcome, shown by many large multi-institution clinical trials,” says Lisa Wiechmann, MD, a breast surgeon at Columbia University Irving Medical Center and senior author on the study. “The current study was really born out of the question of whether this applied to very young women as well, since the trials in question mostly included women with an average age of 55.  We wanted to give young women data that allows them to make a truly informed decision in the risk-benefit equation they calculate when diagnosed with cancer.” 

The researchers analyzed outcomes from 414 women diagnosed with breast cancer at the age of 40 or younger at Columbia University Irving Medical Center between 1995 and 2020. Using a multivariate analysis, they controlled for factors such as age, breast cancer subtype, stage, and genetic mutations including BRCA, to understand the effect of the surgical approach on survival and outcomes in general. They found that there was no statistically significant difference in mortality and recurrence between patients who underwent breast-conserving therapy versus mastectomy. 

“We really wanted to wash out the noise,” says Wiechmann, who is also an associate member of the Herbert Irving Comprehensive Cancer Center. “We wanted to know: if you compare similar patients with similar cancers, is breast-conserving therapy still a safe option for women under 40? And the answer appears to be yes, even within this group of young women.” The researchers note that longer follow-up is needed to comprehensively understand the implications of each therapy option in this younger cohort.

Personalized care is changing the landscape

The findings, while falling in line with prior recommendations, add an important dimension to a growing body of evidence supporting breast conservation as the gold standard for breast cancer surgery, even with diagnoses continuing to rise among younger women. Historically, younger patients have been viewed differently because their cancers can be biologically more aggressive and because they potentially face decades of survivorship ahead. 

Advances in systemic therapies — treatments such as chemotherapy, targeted and immune-therapies, and hormonal therapies that treat cancer throughout the body — are increasingly changing the equation. 

“Our treatments have become much more patient-specific,” Wiechmann says. “The goal now is personalization and, when possible, what we call de-escalation: not overtreating, not undertreating, but finding what’s just right for that individual patient and that specific cancer, like Goldilocks and her porridge.” 

Those advances have also allowed more patients to receive therapy before surgery, shrinking tumors that once would have required mastectomy and making breast conservation possible. In addition, the more personalized guidelines have fine-tuned the requirement for additional treatments post-operatively, and, in extremely selective cases in the research setting, allows some patients to avoid surgery altogether.

Breathing room for an important decision

For many young patients, the decision also extends beyond survival statistics alone. 

“A woman in her 30s may be building a family, finding a partner, navigating work, raising children,” Wiechmann says. “We don’t take mastectomies lightly. They can carry significant physical, emotional, and social consequences.” 

Breast-conserving therapy has fewer complications after surgery. Patients with more advanced or lymph node-positive cancers require radiation even after mastectomy. Radiation after a mastectomy is often complicated by poor wound healing, infection, and even loss of an implant, if reconstruction was done. The reconstruction itself can delay radiation and additional treatment if complications arise.  

“Though counterintuitive, especially for aggressive cancers, with the exception of inflammatory cancer, the best therapy may be breast conservation,” says Wiechmann. “The priority is to cure the cancer a woman walks in with, not prevent the one she may or may never develop in the future.” 

These conversations of “need “ vs “want” give women time and a little breathing room to make the important surgical decisions that will shape their future self, adds Wiechmann, The goal is to complete treatment in the most direct fashion, with the fewest delays and complications.  

That “breathing room,” she says, can matter enormously. Some patients ultimately choose mastectomy later, after treatment is complete and the immediate crisis has passed. Others decide they are comfortable continuing surveillance with mammograms and MRIs. 

“These decisions are personal, complex, and require deep humanity, empathy, and deep compassion for oneself,” Wiechmann says. “Some patients have severe anxiety around ongoing imaging and follow-up. Others feel strongly about preserving their breasts if it’s medically safe to do so. Our job is to help them understand the difference between what they need for survival and what they may want or think they want, for peace of mind.” 

Importantly, the study does not suggest that breast-conserving therapy is appropriate for every patient. Women with certain high-risk genetic mutations, inflammatory breast cancers, or in other selective cases may still require mastectomy as the safest option. 

But for many younger women, the findings provide reassurance that choosing a less extensive surgery does not mean compromising cancer outcomes. 

Wiechmann stresses the importance of acknowledging that these are very personal and nuanced decisions for each person facing a breast cancer diagnosis. “When patients walk into our office, we look at the whole picture. We look at who they are, where they are in their life, and what their primary goals, beyond a cure are,” she says. “This study gives them an additional data point for a very big decision.”